Treatment Duration of IPA

NCT06583512 · tracked via the Priya Life Science China tracker

Sponsor

Peking University People's Hospital

Phase

Observational

Started

2024-12-01

Last updated

2024-12-27

Condition(s) studied

Invasive AspergillosisAntifungal Therapy

Study summary

The goal of this observational study is to identify the duration of posaconazole-initiated antifungal treatment for IPA in patients with hematological malignancies and to explore the value of monitoring immune factors and cells in IPA treatment in order to assess practices in IPA management in Chinese hematology patients including tools to evaluate duration and discontinuation. The main question it aims to answer is:

Does any indicators that could be used to guide the duration of IPA treatment? Does immune factors have value in monitoring IPA treatment? We will not do any interventions to participants. Participants will be monitored routinely for their clinical characteristics, microbiological test( including G/GM Test, Blood culture), Imaging examination, Blood routine, the number and function of immune cells, cytokines(IL-1β/IL-2/IL-4/IL-8/IL-10/IL-12/IL-17/IFN-α/IFN-γ/TNF-α)， and we will collect these datas for analysing.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Informed consent form signed 2. Patient with hematological malignancies 3. Patients with posaconazole-initiated antifungal therapy 4. Treatment duration ≥12w Exclusion Criteria: 1. Refuse to enroll 2. Pregnancy or breastfeeding women 3. Are expected to survive no more than 72 h 4. Fungal or mycobacterial lung co infection at time of IPA diagnosis 5. Hematological malignancy with lung location 6. Disseminated aspergillosis (lung and sinus aspergillosis can be included)

Primary outcome measure(s)

The duration of posaconazole-initiated antifungal treatment therapy for IPA in patients with hematological malignancies — 12 weeks after discontinuation of posaconazole-initiated antifungal therapy
The primary outcome is the duration of posaconazole-initiated antifungal treatment therapy for IPA in patients with hematological malignancies

Trial sites (1)

Facility	City	Region	Status
Peking University People's Hospital	Beijing	Beijing Municipality

More Peking University People's Hospital trials in China

Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors Recruiting

Research on the Application of Patient Navigation-based Management Model of Patients After LEEP Starting soon

IFN-α in Relapse Prevention. Starting soon

ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer Recruiting

CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment Recruiting

Other trials for the same condition

Olorofim Aspergillus Infection Study Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06583512 on ClinicalTrials.gov ↗ ← All trials in China